The NHGRI Genome Sequencing Cost Tracking needs more than an analogy to semiconductor scaling for its cost reductions; you need a defined process for how that comparison actually guided decisions.
Without clear ownership and a detailed breakdown of which specific technological advancements directly contributed to the savings, it's just an interesting observation, not a reliable benchmark.
We need to see the RACI matrix showing who was accountable for each step in reducing those costs, and documented sign-offs for the actual breakthroughs.
For instance, if a new sequencing chemistry cut costs by 50%, there should be a project file with a named project manager and approval signatures detailing that improvement, not just a general nod to Moore's Law.
It's about governance, not just a broad idea.